CN Patent

CN113620957B — 一种胺甲基吡嗪类化合物的制备方法

Assigned to Shengshi Taike Biopharmaceutical Technology (Suzhou) Co.,Ltd. · Expires 2022-04-19 · 4y expired

What this patent protects

本发明涉及一种胺甲基吡嗪类化合物的制备方法，其以2，3‑二甲基吡嗪为起始原料，AIBN引发下，经NCS分批加料实现单氯代，再经盖布瑞尔反应制得2‑甲基‑3‑氨甲基吡嗪，再三氟乙酰化，多聚磷酸关环得到8‑甲基‑3‑(三氟甲基)咪唑[1,5‑a]吡嗪。

USPTO Abstract

本发明涉及一种胺甲基吡嗪类化合物的制备方法，其以2，3‑二甲基吡嗪为起始原料，AIBN引发下，经NCS分批加料实现单氯代，再经盖布瑞尔反应制得2‑甲基‑3‑氨甲基吡嗪，再三氟乙酰化，多聚磷酸关环得到8‑甲基‑3‑(三氟甲基)咪唑[1,5‑a]吡嗪。

Drugs covered by this patent

Patent Metadata

Patent number
CN113620957B
Jurisdiction
CN
Classification
—
Expires
2022-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Shengshi Taike Biopharmaceutical Technology (Suzhou) Co.,Ltd.
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.